Unexpected Widespread Bone Metastases from a BRAF K601N Mutated Follicular Thyroid Carcinoma within a Previously Resected Multinodular Goiter.
BRAF mutation
Bone metastases
Chromosome 19
Follicular thyroid carcinoma
K601N
Next-generation sequencing
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
26
10
2021
pubmed:
30
11
2021
medline:
3
12
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
Follicular thyroid carcinoma (FTC) represents the second most common malignant thyroid neoplasm after papillary carcinoma (PTC). FTC is characterized by the tendency to metastasize to distant sites such as bone and lung. In the last 20 years, the understanding of the molecular pathology of thyroid tumors has greatly improved. Uncommon BRAF non-V600E mutations have been identified and are generally believed to associate with follicular patterned tumors of low malignant potential, particularly non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTPs) (i.e., non-invasive encapsulated follicular variant PTC). We here report for the first time widespread bone metastases from a BRAF K601N mutated follicular tumor.
Identifiants
pubmed: 34843063
doi: 10.1007/s12022-021-09698-7
pii: 10.1007/s12022-021-09698-7
doi:
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-524Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Acquaviva G, Visani M, Repaci Aet al. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology 72: 6-31, 2018.
doi: 10.1111/his.13380
pubmed: 29239040
DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80: 2946-2953, 1995.
pubmed: 7559879
Ito Y, Yabuta T, Hirokawa Met al. Distant and lymph node metastases of thyroid nodules with no pathological evidence of malignancy: a limitation of pathological examination. Endocr J 55: 889-894, 2008; Slutzky-Shraga I, Sternov Y, Robenshtock E, Tzvetov G, Benbassat C, Hirsch D Be Aware of the Patient With Benign Follicular Thyroid Lesion Histology and Rising Thyroglobulin Level. Endocr Pract 24: 740-745, 2018.
Pennelli G, Vianello F, Barollo Set al. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 21: 1393-1396, 2011.
doi: 10.1089/thy.2011.0120
pubmed: 22136270
de Biase D, Acquaviva G, Visani Met al. Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel. Diagnostics (Basel) 10, 2020.
Gandolfi G, Ragazzi M, de Biase Det al. Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. Oncotarget 9: 1813-1825, 2018.
doi: 10.18632/oncotarget.22805
pubmed: 29416733
de Biase D, Acquaviva G, Visani Met al. Next-Generation Sequencing panel for 1p/19q codeletion and IDH1-IDH2 mutational analysis uncovers mistaken overdiagnoses of 1p/19q codeletion by FISH. J Mol Diagn, 2021.
Podda M, Saba A, Porru F, Reccia I, Pisanu A Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors. World J Surg Oncol 13: 193, 2015.
doi: 10.1186/s12957-015-0612-8
pubmed: 26041024
pmcid: 4458056
Kakudo K, Bychkov A, Bai Y, Li Y, Liu Z, Jung CK The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives. Pathol Int 68: 641–664, 2018; Lloyd RV, Osamura RY, Klöppel G, Rosai J: WHO Classification of Tumours of Endocrine Organs. 4th edition, Lyon: International Agency for Research on Cancer, 2017.
Lin X, Zhu B, Liu Y, Silverman JF Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagn Pathol 5: 8, 2010.
doi: 10.1186/1746-1596-5-8
pubmed: 20205756
pmcid: 2822751
Mete O, Asa SL Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24: 1545-1552, 2011.
doi: 10.1038/modpathol.2011.119
pubmed: 21804527
Tickoo SK, Pittas AG, Adler Met al. Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med 124: 1440-1447, 2000.
doi: 10.5858/2000-124-1440-BMFTC
pubmed: 11035572
Ivanova R, Soares P, Castro P, Sobrinho-Simoes M Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch 440: 418-424, 2002.
doi: 10.1007/s00428-001-0543-3
pubmed: 11956824
Baloch ZW, LiVolsi VA Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol 13: 861-865, 2000.
doi: 10.1038/modpathol.3880153
pubmed: 10955452
Seethala RR, Baloch ZW, Barletta JAet al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Mod Pathol 31: 39-55, 2018.
doi: 10.1038/modpathol.2017.130
pubmed: 29052599
Hsiao SJ, Nikiforov YE Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer 21: T301-313, 2014.
pubmed: 24829266
pmcid: 4160369
Xing M Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13: 184–199, 2013.
Duan H, Liu X, Ren X, Zhang H, Wu H, Liang Z Mutation profiles of follicular thyroid tumors by targeted sequencing. Diagn Pathol 14: 39, 2019.
doi: 10.1186/s13000-019-0817-1
pubmed: 31077238
pmcid: 6511182
Torregrossa L, Viola D, Sensi Eet al. Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. J Clin Endocrinol Metab 101: 4413-4420, 2016.
doi: 10.1210/jc.2016-1775
pubmed: 27571181
Wojcik P, Okon K, Osuch C, Klimkowska A, Tomaszewska R BRAF mutations in sporadic colorectal carcinoma from polish patients. Pol J Pathol 61: 23-26, 2010.
pubmed: 20496269
Chapman MA, Lawrence MS, Keats JJet al. Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472, 2011.
doi: 10.1038/nature09837
pubmed: 21430775
pmcid: 3560292
Aggarwal N, Swerdlow SH, Kelly LMet al. Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Mod Pathol 25: 1203-1211, 2012.
doi: 10.1038/modpathol.2012.73
pubmed: 22575864
pmcid: 3434253
Lohr JG, Stojanov P, Carter SLet al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25: 91-101, 2014.
doi: 10.1016/j.ccr.2013.12.015
pubmed: 24434212
pmcid: 4241387
Ng PK, Li J, Jeong KJet al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33: 450–462 e410, 2018.
Chen SH, Zhang Y, Van Horn RDet al. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discov 6: 300-315, 2016.
doi: 10.1158/2159-8290.CD-15-0896
pubmed: 26732095
Yao Z, Torres NM, Tao Aet al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell 28: 370-383, 2015.
doi: 10.1016/j.ccell.2015.08.001
pubmed: 26343582
pmcid: 4894664
Belge G, Roque L, Soares Jet al. Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. Cancer Genet Cytogenet 101: 42–48, 1998; Belge G, Thode B, Bullerdiek J, Bartnitzke S Aberrations of chromosome 19. Do they characterize a subtype of benign thyroid adenomas? Cancer Genet Cytogenet 60: 23–26, 1992.
Bol S, Belge G, Thode B, Bartnitzke S, Bullerdiek J Structural abnormalities of chromosome 2 in benign thyroid tumors. Three new cases and review of the literature. Cancer Genet Cytogenet 114: 75–77, 1999.
Rippe V, Dittberner L, Lorenz VNet al. The two stem cell microRNA gene clusters C19MC and miR-371–3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PLoS One 5: e9485, 2010.
Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer 36: 292-302, 2003.
doi: 10.1002/gcc.10146
pubmed: 12557229
Canzian F, Amati P, Harach HRet al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63: 1743–1748, 1998.
Bonora E, Evangelisti C, Bonichon F, Tallini G, Romeo G Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br J Cancer 95: 1529-1536, 2006.
doi: 10.1038/sj.bjc.6603455
pubmed: 17088905
pmcid: 2360750
Daniell J, Plazzer JP, Perera A, Macrae F An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: a review. Fam Cancer 17: 421-427, 2018.
doi: 10.1007/s10689-017-0037-3
pubmed: 28900777
Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 27: 244-251, 2000.
doi: 10.1002/(SICI)1098-2264(200003)27:3<244::AID-GCC4>3.0.CO;2-7
pubmed: 10679913
Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 79: 547-555, 1999.
pubmed: 10334566
Le Pennec S, Konopka T, Gacquer Det al. Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases. Endocr Relat Cancer 22: 205-216, 2015.
doi: 10.1530/ERC-14-0351
pubmed: 25691441
Sevilla LM, Nachat R, Groot KR, Watt FM Kazrin regulates keratinocyte cytoskeletal networks, intercellular junctions and differentiation. J Cell Sci 121: 3561-3569, 2008.
doi: 10.1242/jcs.029538
pubmed: 18840647